These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35612299)

  • 1. Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC.
    Tao Z; Kuai X; Wang G; Liu S; Liu K; Zhang H; Xia S; Zhu H
    Drug Deliv; 2022 Dec; 29(1):1571-1581. PubMed ID: 35612299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
    Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
    BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
    Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
    Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.
    Socinski MA; Kaye FJ; Spigel DR; Kudrik FJ; Ponce S; Ellis PM; Majem M; Lorigan P; Gandhi L; Gutierrez ME; Nepert D; Corral J; Ares LP
    Clin Lung Cancer; 2017 Jan; 18(1):68-76.e2. PubMed ID: 28341109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis.
    Mutlu H; Bozcuk H; Artaç M; Eser İ
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S6-S11. PubMed ID: 37147977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
    Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M; Orlandi F; Alatorre-Alexander J; Leal T; Cheng Y; Lee JS; Lam S; McCleland M; Deng Y; Phan S; Horn L
    J Clin Oncol; 2021 Feb; 39(6):619-630. PubMed ID: 33439693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
    Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
    BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
    Karam I; Jiang SY; Khaira M; Lee CW; Schellenberg D
    Am J Clin Oncol; 2015 Feb; 38(1):51-4. PubMed ID: 23563211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
    Zhang CY; Sun H; Su JW; Chen YQ; Zhang SL; Zheng MY; Li YF; Huang J; Zhang C; Tai ZX; Cai M; Zhang XC; Su J; Xu CR; Yan HH; Chen HJ; Wu YL; Yang JJ
    Lung Cancer; 2023 Jan; 175():68-78. PubMed ID: 36473332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab: A Review in Extensive-Stage SCLC.
    Frampton JE
    Drugs; 2020 Oct; 80(15):1587-1594. PubMed ID: 32990939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durvalumab: A Review in Extensive-Stage SCLC.
    Al-Salama ZT
    Target Oncol; 2021 Nov; 16(6):857-864. PubMed ID: 34731446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.
    Jiang S; Huang L; Zhen H; Jin P; Wang J; Hu Z
    BMC Cancer; 2021 Dec; 21(1):1308. PubMed ID: 34876060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.
    Paz-Ares L; Garassino MC; Chen Y; Reinmuth N; Hotta K; Poltoratskiy A; Trukhin D; Hochmair MJ; Özgüroğlu M; Ji JH; Statsenko G; Conev N; Bondarenko I; Havel L; Losonczy G; Xie M; Lai Z; Godin-Heymann N; Mann H; Jiang H; Shrestha Y; Goldman JW
    Clin Cancer Res; 2024 Feb; 30(4):824-835. PubMed ID: 37801329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
    Konala VM; Madhira BR; Ashraf S; Graziano S
    Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
    Qin B; Xin L; Liang C; Li L; Song Q; Long Y; Zhang X; Wang D; Shi W; Zhang J; Hu Y; Yang B; Xiong Q
    BMC Cancer; 2024 Jan; 24(1):100. PubMed ID: 38233798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Wang J; Zhou C; Yao W; Wang Q; Min X; Chen G; Xu X; Li X; Xu F; Fang Y; Yang R; Yu G; Gong Y; Zhao J; Fan Y; Liu Q; Cao L; Yao Y; Liu Y; Li X; Wu J; He Z; Lu K; Jiang L; Hu C; Zhao W; Zhang B; Shi W; Zhang X; Cheng Y;
    Lancet Oncol; 2022 Jun; 23(6):739-747. PubMed ID: 35576956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
    Yu H; Chen P; Cai X; Chen C; Zhang X; He L; Zhou Y; Hong S; Zhang B
    Cancer Immunol Immunother; 2022 Mar; 71(3):637-644. PubMed ID: 34297160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age >65 years) using national SEER-Medicare data.
    Kim E; Biswas T; Bakaki P; Dowlati A; Sharma N; Machtay M
    Pract Radiat Oncol; 2016; 6(5):e163-e169. PubMed ID: 27142494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer.
    Kataoka N; Kunimatsu Y; Tachibana Y; Sugimoto T; Sato I; Tani N; Ogura Y; Hirose K; Takeda T
    Thorac Cancer; 2020 Sep; 11(9):2740-2742. PubMed ID: 32706170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
    Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
    Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.